给战友点希望－－硝唑尼特治疗慢肝

山东小兵

原帖由 lemonades 于 2010-3-12 08:05 发表
实在说，都耐药的战友的确可以考虑一试，反正也没啥好担心的了。单独或者联合tdf，起码好过拉米加阿德。至于费用，如果能从我说的网址买到药，两者加起来一个月也就一千多人民币。 ...

那个100美元能买一个月替诺福韦的网址，绝对是个好东西；能造福很多战友

山东小兵

原帖由 齐欢畅2 于 2010-3-11 22:35 发表
和小兵比起来，我这点事又算什么，小兵是拿自己的身体做试验的，这样的战友都值得我们佩服！真正的先行者，希望他们全都痊愈。

一切都在不言中

wtd.2009

硝唑尼特治疗慢肝会耐药吗？

lemonades

反正一年两年的没发现有耐药的。作用于人体而不是病毒。
机理尚且不太清楚。Romark是小实验室，动作不快，加上现在他们忙着做HCV，HIV，和流感等病毒的临床试验，估计一时都做不到耐药来。而且他们还在忙着做缓控释制剂，好申请专利，生产新药等等。所以我的估计，等正式上市，得至少三年。

[ 本帖最后由 lemonades 于 2010-3-12 10:09 编辑 ]

lemonades

不知道这个有人发过没？
Romark reports promising data from hepatitis C virus study
Published: 20-Feb-2009

Romark Laboratories, a privately held biopharmaceutical company, has announced encouraging results from international Phase I and II clinical trials evaluating a controlled release version of nitazoxanide in the treatment of chronic hepatitis C virus infection.
In the Phase II study in treatment-naive patients infected with hepatitis C virus (HCV) genotype 4, 82% (n=17) and 100% (n=16) of patients receiving low and high doses of controlled release nitazoxanide, respectively, experienced undetectable serum HCV RNA (<12 IU/mL) after 12 weeks of combination therapy with peginterferon and ribavirin.

In the Phase I study, Optima HCN-1, a total of 12 healthy adult volunteers were enrolled to evaluate pharmacokinetics following oral administration of nitazoxanide at 675mg or 1,350mg twice daily with food for seven days. This was a randomized, double blind crossover study.

According to the company, the 675mg and 1,350mg twice daily doses of controlled release nitazoxanide produced trough plasma concentrations of tizoxanide, the active metabolite of nitazoxanide, that were approximately 3x and 12x the trough concentrations observed in historical studies using a standard nitazoxanide 500mg tablet. Controlled release nitazoxanide showed favorable safety and tolerability throughout the course of the study, with mild to moderate adverse events (primarily GI-related) reported.

In a subsequent Phase II study, Optima HCN-2, a total of 41 treatment-naive patients with chronic hepatitis C genotype 4 were randomized to receive nitazoxanide at 675mg (n=17), nitazoxanide at 1,350mg (n=16) or placebo (n=8) twice daily for four weeks followed by the same regimen plus standard of care with peginterferon alfa-2a and ribavirin for 36 weeks (48 weeks for the placebo arm).

Interim virologic response rates are as follows: for the low and high-dose nitazoxanide arms, rapid virologic response (RVR, HCV RNA<12 IU/mL after four weeks of combination therapy) 59% and 63% respectively, compared with 50% for the placebo group; complete early virologic response (cEVR, HCV RNA<12 IU/mL after 12 weeks of combination therapy) 82% and 100%, respectively, compared with 63% for the placebo group; early virologic response (EVR, greater than or equal to 2 log10 decline in HCV RNA after 12 weeks of combination therapy) 88% and 100%, respectively, compared with 63% for placebo. In this study, a dose-related decline in serum HCV RNA was observed beginning on day four of combination therapy and was maintained through week 16.

Jean-Francois Rossignol, director of the Romark Institute for Medical Research, said: These data show that controlled release nitazoxanide exhibits favorable pharmacokinetics and tolerability, and - in combination with the standard of care therapy - robust antiviral activity in a small number of patients with HCV genotype 4. We look forward to reporting interim data from our US studies evaluating the standard nitazoxanide tablet in patients with chronic hepatitis C genotype 1 later in 2009.

wtd.2009

谢谢lemonades回复，请战友支持蔡荣教授的药，我6号给他发了短信，从他的回复来看他对这药很有信心，给予鼓励。

lemonades

Nitazoxanide in Treatment of Helicobacter pylori: a Clinical and In Vitro Study
Yvonne Guttner,1 Helen M. Windsor,2 Charlie H. Viiala,1 Leon Dusci,3 and Barry J. Marshall1,2*
Department of Gastroenterology, Sir Charles Gairdner Hospital,1 NHMRC Helicobacter pylori Research Laboratory, Department of Microbiology, University of Western Australia,2 Department of Pharmacology and Toxicology, PathCentre, Perth, Australia3
*Corresponding author. Mailing address: NHMRC Helicobacter pylori Research Laboratory, Department of Microbiology, University of Western Australia, QEII Medical Centre, Nedlands 6009, Australia. Phone: 61-8-9346-4815. Fax: 61-8-9346-4816. E-mail: [email protected].
Received April 3, 2003; Revised June 30, 2003; Accepted September 8, 2003.

Previous studies showed that the incidence of adverse events was dose related, while vital signs, electrocardiograms, and laboratory test results remained unchanged (19). Side effects included loose stools, diarrhea, abdominal pain, flatulence, nausea, vomiting, dyspepsia, xerostomia, discolored urine (yellow-green), and headache (19, 20).

节选，尿是黄绿色的。

山东小兵

Previous studies showed that the incidence of adverse events was dose related, while vital signs, electrocardiograms, and laboratory test results remained unchanged (19). Side effects included loose stools, diarrhea, abdominal pain, flatulence, nausea, vomiting, dyspepsia, xerostomia, discolored urine (yellow-green), and headache (19, 20).
loose stools(粪便变稀，这个服药的最开始两天有的), diarrhea（腹泻，这个我没有）, abdominal pain（肚子痛，这个没有）, flatulence（胃肠胀气，这个有吧，这两天有屁了）, nausea（恶心，这个没有）, vomiting（呕吐，这个没有）, dyspepsia（消化不良，这个算有吧，这两天胃口稍微变弱，原来四两米饭，现在三两的次数多了一些，不过我觉得跟睡眠质量稍微降低有关）, xerostomia（口干，稍微有点吧）, discolored urine (yellow-green)（小便变绿黄色，这个很明显，服药6小时左右，最强）, and headache (19, 20)（头痛，。。。这个没有，不过睡眠质量最近几天略下降）.

二次修改：
再就是平时 我如果睡醒了，就有很强的运动欲望（我能骑自行车 一天奔个120-150公里，脚有伤，但是只要精神好，也想出去爬山活动什么的），
但是最近没有，略有体乏吧

[ 本帖最后由 山东小兵 于 2010-3-12 13:06 编辑 ]

富贵数字

原帖由 山东小兵 于 2010-3-12 11:31 发表
loose stools(粪便变稀，这个服药的最开始两天有的), diarrhea（腹泻，这个我没有）, abdominal pain（肚子痛，这个没有）, flatulence（胃肠胀气，这个有吧，这两天有屁了）, nausea（恶心，这个没有）, vomiting（呕吐，这个没有）, dyspepsia（消化不 ...

wtd.2009

山东小兵加油！